Bettina Hamelin

Bettina Hamelin currently serves as President of Innovative Medicines Canada since April 2024, following a tenure as President and CEO of Ontario Genomics from August 2017 to March 2024. Prior to these roles, Bettina was Vice President of Research Partnerships at the Natural Sciences and Engineering Research Council of Canada (NSERC) from September 2015 to July 2017, where leadership was provided in developing innovation portfolios and fostering partnerships between academia and industry. Bettina's extensive experience in the pharmaceutical sector includes various leadership positions at Pfizer from August 2006 to 2015, emphasizing strategic medical affairs and R&D partnerships. Earlier positions included Associate Director at Shire BioChem Pharma and Associate Professor at Université Laval, focusing on pharmacokinetics and drug metabolism research. Bettina Hamelin holds an EMBA in Healthcare from The University of British Columbia and a PharmD from the University of Kentucky, along with postdoctoral training in pharmacokinetics and pharmacogenetics.